Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

blonca9
Nov 18, 2024
1 min read

CEO David Happel describes how this fatty acid synthase (FASN) inhibitor works, and the AI method suggesting the therapy is having an impact on liver fibrosis. Plus, plans for initiating a phase 3 study.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight